Multicenter Phase II Study of Tivozanib (AV‐951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer

Overview of attention for article published in Oncologist, April 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

So far, Altmetric has seen 1 X post from an account with 363 followers.

[VEGF] Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractor... http://t.co/0C51P3RoD3 PM

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.